EPISODE · Jan 2, 2026 · 22 MIN
Destiny-Breast09: Is T-DXd Rewriting First-Line HER2+ Metastatic Breast Cancer? - Dr. Mark Pegram & Dr. Fengting Yan
from Community Health Media · host Community Health Media
Recorded at the 2025 San Antonio Breast Cancer Symposium, Dr. Mark Pegram (Stanford University) and Dr. Fengting Yan (Swedish Cancer Institute) break down the data that may redefine first-line treatment for HER2-positive metastatic breast cancer.This expert discussion dives deep into DESTINY-Breast09, exploring unprecedented progression-free survival results with T-DXd + pertuzumab, implications for brain metastases, response durability, toxicity management, and whether the long-standing CLEOPATRA regimen is finally being challenged.From induction–maintenance strategies to personalized treatment selection, this conversation offers real-world clinical insight into what’s next for HER2+ disease.🎧 A must-watch for oncologists navigating the next era of HER2-targeted therapy.#HER2Positive #BreastCancer #MetastaticBreastCancer #TDXd #DestinyBreast09 #CLEOPATRA #Oncology #MedicalOncology #BreastOncology #ADC #AntibodyDrugConjugates #SABCS2025 #CancerResearch #ClinicalTrials–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media
Embed this episode
Ready to play
Destiny-Breast09: Is T-DXd Rewriting First-Line HER2+ Metastatic Breast Cancer? - Dr. Mark Pegram & Dr. Fengting Yan
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.